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ABSTRACT
We previously reported data from 103 patients with hematologic malignancies (median age 54 years) who
received peripheral blood stem cell (PBSC) grafts from HLA-matched unrelated donors after nonmyelo-
ablative conditioning and were given postgrafting immunosuppression consisting of mycophenolate
mofetil (MMF; administered from day 0 until day 40 with taper through day 96) and cyclosporine (CSP;
given from day 3 to day 100, with taper through day 180) (historical patients). The incidences of grade
II-IV acute and extensive chronic graft-versus-host disease (aGVHD, cGVHD) were 52% and 49%,
respectively, and the 1-year probabilities of relapse, nonrelapse mortality (NRM), and progression-free
survival (PFS) were 26%, 18%, and 56%, respectively. Here, we treated 71 patients with hematologic
malignancies (median age 56 years) with unrelated PBSC grafts and investigated whether postgrafting
immunosuppression with an extended course of MMF, given at full dosing until day 150 and then tapered
through day 180, and a shortened course of CSP, through day 80, would promote tolerance induction
and reduce the incidence of GVHD (current patients). We observed 77% grade II-IV aGVHD and 45%
extensive cGVHD (P  .03, and P  .43, respectively, in current compared to historical patients). The
1-year probabilities of relapse, NRM, and PFS were 23%, 29%, and 47%, respectively (P  .89, P  .02,
and P  .08 compared to the historical patients). We conclude that postgrafting immunosuppression with
extended MMF and shortened CSP failed to decrease the incidence of GVHD among unrelated PBSC
recipients given nonmyeloablative conditioning.
© 2007 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
To extend allogeneic hematopoietic cell trans-
lantation (HCT) from unrelated donors (URD) to
nclude older patients with hematologic malignancies, rhose with comorbid conditions, and those who had
ailed high-dose HCT, several groups of investigators
ave developed reduced-intensity (RIC) or nonmy-
loablative conditioning regimens [1-5], which have
elied mainly or exclusively on immune-mediated
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F. Baron et al.1042raft-versus-tumor effects for tumor eradication [6-9].
ased on experimental canine studies [10] and on
ubsequent clinical trials in HLA-identical sibling re-
ipients [8], we investigated a nonmyeloablative regi-
en consisting of ﬂudarabine, 3  30 mg/m2, and 2
y total body irradiation (TBI) for unrelated HCT
5,11-13]. Postgrafting immunosuppression included
ycophenolate mofetil (MMF) and cyclosporine
CSP).
In a previous prospective study, MMF was given at
5 mg/kg orally thrice daily, from the evening of day
through day 40 with taper through day 96, and
SP was given at 5 mg/kg orally twice daily, from day
3 to day 100, with taper through day 180 [14].
ustained engraftment was achieved in 95% of pa-
ients, and cumulative incidences of grade II-IV acute
raft-versus-host disease (aGVHD) and extensive
hronic GVHD (cGVHD) were 52% and 49%, re-
pectively. Two-year probabilities of progression-free
urvival (PFS), relapse, and nonrelapse mortality
NRM) were 49%, 31%, and 19%, respectively.
Several studies have suggested that CSP prevented
ctivation-induced death of T cells, and thus poten-
ially delayed the eradication of alloreactive donor T
ells, preventing tolerance induction [15-18]. Con-
ersely, antimetabolites such as MMF could delete
lloreactive T cells by inducing apoptosis [19,20],
hereby favoring tolerance induction. Based on these
xperimental ﬁndings, we investigated whether earlier
iscontinuation of CSP at day 80 along with pro-
onged MMF administration (taper initiated at day
50) would decrease the incidence of GVHD after
onmyeloablative unrelated HCT.
ATIENTS AND METHODS
ligibility Criteria
Eligibility criteria were those previously reported
14]. Brieﬂy, patients were included in this multi-
nstitutional international protocol if they had hema-
ologic malignancies treatable by unrelated HCT and
ere older than 50 years. Younger patients were can-
idates if they were considered at risk for transplant-
elated mortality (TRM) with myeloablative condi-
ioning because of medical comorbidities or preceding
ailed high-dose HCT or if they refused conventional
CT. Seventy-one patients were enrolled from Oc-
ober 2003 to January 2005. Their characteristics are
hown in Table 1. Brieﬂy, median age was 56 (range:
5-75) years. Diagnoses were acute myelogenous leu-
emia (AML; n  20), myelodysplastic syndrome
MDS; n  14), non-Hodgkin lymphoma (n  11),
udarabine-refractory chronic lymphocytic leukemia
n  8), multiple myeloma (n  6), chronic myelog-
nous leukemia (CML; n 5), Hodgkin lymphoma (n
4), myeloproliferative disorders (n  2), and acute tymphoblastic leukemia (ALL; n  1). Forty-seven
atients were 50 years old, 16 had failed high-dose
CT, 7 had planned tandem autologous-allogeneic
CT, and 1 had morbid obesity. Sixty-nine percent of
he patients had HCT-comorbidity index (HCT-CI)
cores  1, including 41% who had scores 3. Pa-
ients received HCT at 10 centers including the Fred
utchinson Cancer Research Center (FHCRC; n 
5), Emory University in Atlanta (n  10), University
f Leipzig (Germany, n  6), University of Tuebin-
en (Germany, n  4), Oregon Health & Science
niversity in Portland (n  4), Rocky Mountain Can-
er Center in Denver (n  3), University of Utah in
alt Lake City (n  3), VA Puget Sound Health Care
ystem in Seattle (n  2), Medical College Wisconsin
n Milwaukee (n 2), and Stanford University in Palo
lto (n  2). The protocol was approved by the
nstitutional review boards (IRB) at the FHCRC and
ach of the collaborating sites. All patients signed
onsent forms approved by the local IRB.
tem Cell Source and HLA Matching
All patients were given peripheral blood stem cells
PBSC). Compatibility between patients and donors
or HLA-A, -B, -C, -DRB1, and -DQB1 alleles was
ssessed by high-resolution DNA techniques [5]. Sixty-
ve pairs were matched at the allelic levels for all 10
lleles at HLA-A, -B, -C, -DRB1, and -DQB1,
hereas 6 pairs were mismatched for a single HLA-A
n  2), HLA-B (n  3), or HLA-C (n  1) allele.
onditioning Regimen and
ostgrafting Immunosuppression
Conditioning included ﬂudarabine, 30 mg/m2/day
n days 4, 3, and 2, in all patients. Sixty-eight
eceived 2 Gy total body irradiation (TBI) (day 0),
hereas 3 patients with CML were given 3 Gy TBI in
n attempt to reduce the risk of graft rejection. Post-
rafting MMF was given at 15 mg/kg orally thrice
aily from the evening of day 0 until day 30, at 15
g/kg orally twice daily from day 31 until day
150, and then tapered from day 150 until day 180.
SP was given at 5 mg/kg orally twice daily from day
3 to day80 and then discontinued without taper at
ay 80 in the absence of GVHD.
VHD Grading and Therapy, and Supportive Care
Diagnosis, clinical grading, and treatment of
VHD were performed according to established cri-
eria [21]. Treatment of GVHD was based on the
ttending physicians’ assessment of the severity of
VHD. Initial treatment usually consisted of pred-
isolone, 1-2 mg/kg/day with taper initiated within 14
ays. If already discontinued, CSP was usually re-
umed at full doses. Steroid-refractory aGVHD was
reated per available investigational protocols or other
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Nonmyeloablative Unrelated HCT 1043alvage regimens. Extensive cGVHD was usually
reated with prednisone (1 mg/kg) with or without
lternate-day CSP [22].
Standard prophylaxis against infections was used
23]. Patients with cGVHD requiring systemic im-
unosuppressive therapy remained on prophylaxis
or Pneumocystis carinii and pneumococcal infec-
able 1. Patients
Characteristic
edian patient age, years (range)
ecipient sex, #M (%)/#F (%)
emale donor/male recipient, # patients (%)
iagnosis at the time of nonmyeloablative
conditioning, # (%) patients
AML/ALL
CR1-2
CR>2
>CR
Chronic myeloid leukemia
CP1
CP2 or AP
Fludarabine-refractory chronic lymphocytic leukemia
Myelodysplastic syndrome
RA
RAEB/CR1
tAML CR1/CR2
Multiple myeloma
CR/PR/Ref
Non-Hodgkin lymphoma
CR/PR
Stable
Ref/rel
Hodgkin lymphoma
CR/PR
Ref/rel
yeloproliferative syndrome other than chronic
myelogenous leukemia
aldenströms macroglobulinemia
enal cell carcinoma
isease, # patients (%)
Indolent*
Aggressive†
omorbidity at HCT (HCT-CI score [27), # pts (%)
0
1-2
>3
onor, # pts (%)
HLA-allele Match
1 allele HLA-mismatch
BSC dose, median (range)
CD34 cells (106/kg recipient)
T cells (108/kg recipient)
ML indicates acute myelogenous leukemia; ALL, acute lymphobl
chronic phase; AP, accelerated phase; RA, refractory anemia; RA
G-CSF-mobilized peripheral blood stem cells.
Deﬁned as acute myelogenous leukemia in ﬁrst complete remission
syndrome-refractory anemia, chronic myelogenous leukemia i
Hodgkin lymphoma, multiple myeloma in partial or complete r
All other diagnoses.ions. nDisease-dependent restaging after HCT occurred
onthly for the ﬁrst 3 months and then at 6 months,
year, and yearly thereafter. Percentages of donor-
ost chimerism were assessed by ﬂuorescent in situ
ybridization for X and Y chromosomes (FISH) in
ecipients of sex-mismatched HCT, or by polymerase
hain reaction (PCR)-based ampliﬁcation of variable-
rent Patients
tocol #1668)
(n  71)
Historical Patients
(Protocol #1641)
(n  103) P Value
6 (15-75) 54 (17-69.6) NS
49/22 63/40 NS
1 (15%) 21 (20%) NS
1 (30) 24 (23)
6 (23) 21 (20)
4 (6) 1 (1)
1 (1) 2 (2)
5 (7) 5 (5)
3 (4) 3 (3)
2 (3) 2 (2)
8 (11) 13 (13)
4 (20) 9 (9)
4 (6) 2 (2)
3 (4) 4 (4)
7 (10) 3 (3)
6 (8) 11 (11)
3)/3(4)/1(1) 2(2)/6(6)/3(3)
1 (15) 24 (23)
5(7)/1(1) 9(9)/6(6)
0 1 (1)
5 (7) 6(6)/2(2)
4 (6) 8 (8)
1(1)/1(1) 1(1)/3(3)
2 (3) 1(1)/3(3)
2 (3) 3 (3)
0 2 (2)
0 4 (4)
1 (44) 40 (39)
NS0 (56) 63 (61)
NS
2 (31) 30 (29)
0 (28) 38 (37)
9 (41) 35 (34)
5 (92) 92 (89)
NS6 (8) 11 (11)
4 (1.1-30.0) 7.3 (0.8-26.3) NS
6 (0.8-6.7) 2.7 (0.3-9.3) NS
kemia; CR, complete remission; Rel, relapse; Ref, refractory; CP,
fractory anemia with blast excess; tAML, secondary AML; PBSC,
ymphoblastic leukemia in ﬁrst complete remission, myelodysplastic
chronic phase, chronic lymphoblastic leukemia, low-grade non-
n, and Waldenstrom macroglobulinemia.Cur
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F. Baron et al.1044eat (STR) sequences unique to donors and hosts if
atients and donors were sex mismatched [13].
Persistent, progressive, or relapsed malignancies
n the absence of severe manifestations of aGVHD
nd cGVHD were treated by rapid taper and discon-
inuation of systemic immunosuppression to initiate
raft-versus-tumor effects. In addition, 2 patients with
ow (30%) donor T cell chimerism were given pen-
ostatin (4 mg/m2), followed 2 days later by donor
ymphocyte infusion (DLI) on a separate protocol as
reliminarily reported [24], in an attempt to avert
raft rejection [25,26].
tatistical Analyses
Data were analyzed as of April 18, 2006. Overall
urvival (OS) and PFS were calculated by the
aplan-Meier method. Cumulative incidence es-
imates were calculated for graft rejection, graft
ailure, aGVHD and cGVHD, life-threatening
VHD, steroid initiation, progression/relapse, and
RM. Hazard ratios were estimated by Cox regres-
ion models. To better compare the outcomes be-
ween the 2 protocols, multivariate models adjust-
ng for pretransplant risk factors were constructed.
retransplant risks factors included in the models
ere aggressive versus indolent disease, HLA-
ismatch between donors and recipients versus not,
atient CMV status, patient age (over 50 versus
ot), female to male recipient versus not, and co-
orbidity at HCT (assessed by the HCT-comor-
idity index [HCT-CI]) [27]. By protocol, graft
ailure was deﬁned as Common Toxicity Criteria
CTC) grade IV thrombocytopenia and neutropenia
ersisting/occurring after day 21, lasting more
han 2 weeks, and refractory to hematopoietic
rowth factors. Graft rejection was deﬁned as the
nability to detect or loss of detection of 5%
onor T cells [26]. All P values refer to hazard ratio
omparisons, and are 2 sided.
able 2. Outcomes for Current (n  71) Relative to Historical (n  1
Endpoint
Cumulative Inciden
Historical Patients
verall survival 68%
rogression-free survival 56%
elapse/progression 26%
onrelapse mortality 18%
rade II-IV aGVHD 52%
rade III-IV aGVHD 15%
xtensive cGVHD 49%
VHD indicates graft-versus-host disease; aGVHD, acute GVHD;
conﬁdence interval.
Adjusted for disease risk (aggressive versus indolent disease), one H
serostatus, recipient age (over 50 years old versus not), female d
3).HR for outcomes in current relative to historical patients. HR 1 refersESULTS
ngraftment
Median donor T cell chimerism levels on days
28, 180, and 365 after HCT were 89%, 99%,
nd 100%, respectively, in current patients, versus
2%, 99%, and 100% in historical patients. Sustained
ngraftment was achieved in 68 current patients
96%) versus in 98 historical patients (95%). Two of 3
urrent CML patients conditioned with 3 Gy TBI had
ither protocol deﬁned primary graft failure (without
ulﬁlling the protocol’s criteria for graft rejection [see
elow]), or graft rejection.
VHD
The cumulative incidences of grade II-IV and
rade III-IV aGVHD were 77% and 26% among
urrent patients versus 52% (P  .03; P  .02 after
djusting for pretransplant risk factors; Table 2) and
5% (P  .11; P  .16 after adjusting for pretrans-
lant risk factors; Table 2) among historical pa-
ients, respectively (Figure 1A). Speciﬁcally, grades
I, III, and IV aGVHD were seen in 51%, 16%, and
0% of current patients, respectively, versus 38%,
1%, and 4% of historical patients, respectively.
ne of the 7 current cases of grade IV aGVHD
ccurred after abrupt discontinuation of postgraft-
ng immunosuppression for progressive disease, and
nother after pentostatin (4 mg/m2) and DLI for
revention of graft rejection. Three additional cases
f grade IV aGVHD occurred after discontinuation
f CSP on day 80. Seven of 11 historical patients
ismatched with their donor for a single HLA-class
allele experienced grade II-IV aGVHD (including
patient with grade IV aGVHD), whereas 5 of 6
urrent patients who mismatched with their donor
or a single HLA-class 1 allele had grade II-IV
GVHD (including 1 patient with grade IV
GVHD). The 1-year cumulative incidence of ex-
tients
Year Adjusted*
HR† (95% CI)
Adjusted*
P Valuerrent Patients
55% 1.58 (1.0-2.5) .05
47% 1.51 (1.0-2.3) .05
23% 1.22 (0.7-2.2) .50
29% 1.93 (1.1-3.5) .03
77% 1.67 (1.1-2.5) .02
26% 1.65 (0.8-3.3) .16
45% 0.85 (0.5-1.3) .48
D, chronic GVHD; CMV, cytomegalovirus; HR, hazard ratio; CI,
lele mismatch between donor and recipient or not, recipient CMV
male recipient, and comorbidity at HCT (HCT-CI score 0, 1-2,03) Pa
ce at 1
Cu
cGVH
LA-al
onor toto worse outcomes.
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Nonmyeloablative Unrelated HCT 1045ensive cGVHD was 45% among current patients
ersus 49% among historical patients (P  .43;
 .48 after adjusting for pretransplant risk factors
Table 2 and Figure 1B).
elapse, NRM, Survival
The current and historical 1-year cumulative inci-
ences of relapse/progression were similar: 23% versus
6%, respectively (P  .89; P  .50 after adjusting for
retransplant risk factors; Table 2). However, the cur-
ent 1-year cumulative incidence of NRM was higher
29%) compared to the historical one of 18% (P  .02;
 .03 after adjusting pretransplant risk factors; Table
). To determine whether abrupt CSP discontinua-
ion on day 80 was in part responsible for the
ncreased current NRM, we compared NRM in
atients with grade II-IV aGVHD before day 80,
ho therefore were continued on CSP, and in pa-
igure 1. Cumulative incidences of grades II acute GVHD [aGV
ncluded in the current protocol (protocol #1668; extended MM
1641; n  103). Progression-free survival in patients included in
f nonrelapse mortality in the current and in the historical protocols
GVHD before day 80.ients without grade II-IV aGVHD on day 80 (hose CSP was discontinued. Current and histori-
al NRMs were comparable in patients with
GVHD before day 80 (hazard ratio [HR] 1.12
0.4-3.2], P  .83), whereas NRM was higher in
urrent patients without grade II-IV aGVHD on
ay 80 (HR 10.1 [3.4-30], P  .0001) (Figure 1C).
urrent causes of death in these patients included
rade III (n  1) or grade IV (n  4) aGVHD,
GVHD (n  3), graft failure (n  2), infection (n
1), pulmonary embolism (n  1), chronic heart
ailure (n  1), and unknown (n  1). Taken to-
ether, these data suggested that early CSP discon-
inuation on day 80 contributed to higher NRM.
The current 1-year OS/PFS were 55% and 47%
ersus 68% (P  .06; P  .05 after adjusting for
retransplant risk factors) and 56% (P  .08; P 
05 after adjusting for pretransplant risk factors;
able 2), respectively, among historical patients
(A), III-IV aGVHD (B), and extensive cGVHD (C), in patients
truncated CSP, n  71), or in the historical protocol (protocol
rent protocol or in the historical protocol (D). Cumulative incidences
patients who experienced (E) or did not experience (F) grade II-IVHD]
F and
the cur
amongFigure 1D).
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F. Baron et al.1046ISCUSSION
GVHD with or without infection has been the
eading cause of NRM after transplantation following
onmyeloablative conditioning [9,28]. Because CSP
15-18] but not MMF inhibited activation-induced
eath of T cells [19,20], we reasoned that early CSP
iscontinuation combined with extended MMF ad-
inistration might help promoting tolerance induc-
ion, and reduce the incidences of late aGVHD and
GVHD.
However, we observed that prolonging MMF and
runcating CSP administration failed to reduce GVHD.
n the contrary, whereas cGVHD was comparable in
he 2 protocols, grade II-IV aGVHD was signiﬁcantly
ore frequent among current than historical patients.
here are 2 possible explanations for this ﬁnding.
irst, from day 28 to day 40, MMF was given
wice a day in current versus three times a day in
istorical patients. That explanation is unlikely, how-
ver, given that three times a day MMF administra-
ion, although apparently effective in reducing the risk
f graft rejection, did not alter the GVHD incidence
ompared to original twice a day MMF administration
5]. Second, and most likely, our hypothesis of toler-
nce induction through early discontinuation of the
alcineurin inhibitor and continuation of the antime-
abolite was incorrect. As a result, more current than
istorical patients developed aGVHD after day 80
ncluding 4 with grade IV GVHD. Apparently, ad-
inistration of a calcineurin inhibitor for at least 6
onths after HCT is needed for successful establish-
ent of graft-host-tolerance. This concept is in agree-
ent with the recent observation by Burroughs et al.
29] in patients given grafts from related donors that
xtending CSP administration through day 180
ompared to CSP discontinuation at earlier time
oints reduced the incidence of grade III-IV aGVHD
rom 15%-20% to 5% [29].
Likely, as a result of the increase in aGVHD,
RM in current patients was signiﬁcantly higher than
mong historical patients. The increase in NRM oc-
urred among patients without aGVHD on day 80,
hereas it was similar among patients who experi-
nced aGVHD before day 80 and, therefore, con-
inued receiving CSP. Strong associations between
GVHD and NRM have been reported by us and
thers after nonmyeloablative or RIC [9,30-34]. Not
urprisingly, the increased NRM among current pa-
ients translated into both decreased OS/PFS com-
ared to historical patients.
The increased incidence of grade II-IV aGVHD
n current patients did not translate into lower risk of
elapse. We acknowledge that caution is in order
hen comparing relapse incidences between the 2
roups of patients given the heterogeneity of under-
ying diseases. However, this observation is in agree- cent with previous studies by our group [9] and by
thers [30,35,36], showing that occurrence of grade
I-IV aGVHD was not signiﬁcantly associated with
ower risk of relapse after nonmyeloablative condi-
ioning. In contrast, occurrence of cGVHD has been
igniﬁcantly associated with lower risk of relapse after
onmyeloablative conditioning, particularly in pa-
ients with AML or MDS [9,35,36].
Although 96% of current patients achieved sus-
ained engraftment, similar to what was observed in
he previous protocol (95%), 2 patients with CML had
raft rejection/failure, even though the TBI dose had
een increased from 2 Gy to 3 Gy. A high rate of graft
ejection among CML patients given unrelated grafts
fter relatively more intense RIC has been reported by
ther investigators [1,37]. A graft failure rate of 44%
3 of 8 patients) was described after an RIC regimen
hat combined ﬂudarabine (150 mg/m2), i.v. busulfan
6.6 mg/kg), and ATG [37], whereas 5 of 22 evaluable
atients given unrelated marrows after conditioning
ith 5.5 Gy TBI and cyclophosphamide also experi-
nced graft failure [1].
In conclusion, postgrafting immunosuppression
ith extended MMF and shortened CSP increased the
ncidence of aGVHD in unrelated HCT recipients
iven nonmyeloablative conditioning. It would appear
hat extending calcineurin inhibitors for 6 months is
equired for better control of GVHD. Extending use
eyond that time is of questionable value, given that a
rospective randomized study comparing 6 versus 24
onths CSP administration failed to show differences
n outcomes [38].
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